Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
The focus of my research is to understand mechanisms of sensitivity and resistance to kinase inhibitors and to translate laboratory based observations into therapeutic treatments for patients with cancer. To achieve this goal we have taken a multifaceted approach; combining cell biological and biochemical studies with genomic studies of human tumors from patients treated with kinase inhibitors.
Global advances and future directions in lung cancer care: expert consensus and strategic priorities
The SOS1 inhibitor BI 1701963 as monotherapy or in combination with trametinib in patients with KRAS mutation-positive solid tumors.
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
Transferrin receptor targeting chimeras for membrane protein degradation.
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Sevabertinib in Advanced <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Patritumab deruxtecan (HER3-DXd) in resistant <i>EGFR</i> -mutated ( <i>EGFR</i> m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.
First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS <sup>G12C</sup> -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry.
Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
P3.18.61 KRYSTAL-4: Phase 3 Study of Adagrasib Plus Pembrolizumab and Chemotherapy Intreatment-Naïve, Advanced KRAG12C-Mutated NSCLC
Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC
A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors.
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.
Supplementary Table S1 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors